February 16, 2006 -- GPC Biotech completed its filing for approval of satraplatin, a prostate cancer drug; Gilead received Priority Review for ambrisentan, a treatment for PAH; Onyx used earnings to continue its week-long march upward; the FDA accepted a filing from ZymoGenetics for approval of recombinant human thrombin; Inspire Pharma in-licensed the US and Canadian rights to AsaSite, a topical anti-infective for the eye; Valeant acquired the rights to anti-nausea drug nabilone for the UK and Europe; and OrthoLogic found that its synthetic peptide Chrysalin was effective in a post-hoc defined sub-group. The Centient Biotech 200™ fell 22 points to 4054, a loss of .55%. More details...
